NEW YORK, NY / ACCESSWIRE / May 11, 2021 /Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
BELLUS Health Inc. (NASDAQ:BLU)
CONTACT JAKUBOWITZ ABOUT BLU:
Class Period: September 5, 2019 - July 5, 2020
Lead Plaintiff Deadline: May 17, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: while BLU-5937's "high selectivity" contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company's Phase 2 trial.
Canoo Inc. (NASDAQ:GOEV)
CONTACT JAKUBOWITZ ABOUT GOEV:
Class Period: August 18, 2020 - March 29, 2021
Lead Plaintiff Deadline: June 1, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's engineering services was not a viable business, would not provide meaningful revenue in 2021, and would not reduce operational risk; (ii) the Company would no longer be focused on its subscription-based business model; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
ChemoCentryx, Inc. (NASDAQ: CCXI)
CONTACT JAKUBOWITZ ABOUT CCXI:
Class Period: November 26, 2019 - May 3, 2021
Lead Plaintiff Deadline: July 6, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
1140 Avenue of the Americas
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.